Terlipressin, sold under the brand name Terlivaz among others, is an analogue of vasopressin used as a vasoactive drug in the management of low blood pressure. It has been found to be effective when norepinephrine does not help. Terlipressin is a vasopres + some more technical info: chemically it is a synthetic N-triglycyl prodrug of lysine-vasopressin, a cyclic 12-amino-acid peptide that is cleaved enzymatically to release the active lysine-vasopressin at target sites. Pharmacodynamically it is a selective V1 receptor agonist with predominant splanchnic and systemic vasoconstrictor effects that reduce portal venous inflow and increase systemic vascular resistance, supporting arterial pressure in vasodilatory circulatory failure. Compared with native vasopressin it has a longer duration of action due to slower enzymatic conversion and reduced renal clearance. Key analytical and clinical characteristics include peptide sequence confirmation by LC-MS and peptide mapping, potency assays by receptor binding or functional vascular assays, and monitoring for dose-related ischemic adverse events in patients with significant cardiovascular disease.
Parent: Terlipressin
Parent: Terlipressin
Parent: Terlipressin
Parent: Terlipressin
Parent: Terlipressin
Parent: Terlipressin
Parent: Terlipressin
Parent: Terlipressin
Parent: Terlipressin
Parent: Terlipressin
Pharmaceutical-grade terlipressin is manufactured and released with a high purity profile by validated chromatographic methods; typical purified bulk material shows greater than 95 percent area by RP-HPLC for the main peak. Known related compounds and impurities that are routinely monitored include N-terminally truncated peptides, incomplete deacylation or over-cleaved forms, oxidized methionine species, deamidated asparagine or glutamine variants, peptide dimers or aggregates, and process-related impurities such as residual solvents and cleavage reagents. Typical product specifications control individual unidentified related substances at or below about 0.5 percent relative area and total related substances below about 2.0 percent, with established acceptance criteria confirmed by orthogonal methods such as LC-MS and peptide mapping; limits for heavy metals and microbial bioburden follow applicable pharmacopeial or regulatory requirements.
Terlipressin is used as a vasoactive agent to raise arterial blood pressure in conditions of severe vasodilation and to reduce portal hypertension; clinical indications include treatment of acute variceal bleeding and management of hepatorenal syndrome where vasoconstrictive support of systemic and splanchnic circulation is required.
Terlipressin produces splanchnic vasoconstriction via V1 receptor activation, which lowers portal venous pressure and portal venous inflow; this reduction in portal pressure decreases stress on variceal veins, helps control active bleeding from esophageal varices, and improves hemostasis when used alongside endoscopic interventions.
Terlipressin is a vasoconstrictor; it is a V1 receptor agonist that causes constriction of vascular smooth muscle, especially in the splanchnic circulation, thereby increasing systemic vascular resistance and arterial pressure.
By activating vascular V1 receptors, terlipressin causes constriction of splanchnic arterioles and venules, reducing portal blood inflow and portal pressure; the decreased hydrostatic pressure in variceal vessels reduces bleeding and helps clot formation to be maintained, often in combination with endoscopic therapies for definitive control.
